Novel adenovirus vaccine therapy for the treatment of recurrent respiratory papillomatosis

A therapeutic vaccine using adenovirus vectors encoding modified HPV6 and HPV11 polypeptides addresses the challenge of RRP by enhancing T-cell response, reducing surgical interventions and papilloma recurrence.

JP2026518240APending Publication Date: 2026-06-04PRECIGEN INC
0 Cites 0 Cited by

Patent Information

Application Number
JP2025568620
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-22
Filing Date
2024-05-22
Publication Date
2026-06-04

AI Technical Summary

Technical Problem

There is no effective and safe treatment for recurrent respiratory papillomatosis (RRP) caused by human papillomavirus (HPV) types 6 or 11, leading to frequent surgical interventions and psychological distress, with existing immunotherapies failing to eradicate the chronic persistence of latent HPV in seemingly normal mucosa.

Method used

Development of a therapeutic vaccine using adenovirus vectors encoding modified HPV6 and HPV11 polypeptides, including E2 and E4 proteins, to prime the T-cell response against HPV antigens, potentially reducing the need for surgical interventions and enhancing immune response.

Benefits of technology

The vaccine induces a strong HPV-specific T-cell response, leading to reduced papilloma recurrence and decreased frequency of surgical procedures, improving clinical outcomes for RRP patients.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

Multiantigenic human papillomavirus (HPV) molecular vaccine constructs for use and treatment of HPV-related disorders and conditions, e.g., HPV molecular vaccines targeting HPV6 and HPV11-associated recurrent respiratory papillomatosis (RRP).
Need to check novelty before this filing date? Find Prior Art